Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma

[1]  Veerendra Koppolu,et al.  Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma , 2018, Journal of cancer research and therapeutics.

[2]  J. Utikal,et al.  The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study , 2018, Oncotarget.

[3]  D. Schadendorf,et al.  Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[4]  M. Weichenthal,et al.  Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. , 2018, European journal of cancer.

[5]  É. Drumez,et al.  BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response , 2017, Melanoma research.

[6]  R. Dummer,et al.  Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600‐mutated melanoma , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  Bart Neyns,et al.  Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. , 2017, The Lancet. Oncology.

[8]  P. Wolter,et al.  Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination , 2017, Melanoma research.

[9]  F. Cappuzzo,et al.  Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. , 2016, Lung cancer.

[10]  K. Flaherty,et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.

[11]  C. Lebbé,et al.  BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma , 2015, Melanoma research.

[12]  J. Mackiewicz,et al.  Resistance to Vemurafenib Can Be Reversible After Treatment Interruption , 2014, Medicine.

[13]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[14]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[15]  S. Pradervand,et al.  Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression , 2013, Clinical Cancer Research.

[16]  K. Flaherty,et al.  Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[18]  B. Neyns,et al.  Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.

[19]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[20]  Y. Hatanaka,et al.  Sorafenib rechallenge in patients with metastatic renal cell carcinoma , 2012, BJU international.

[21]  J. Blay,et al.  Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib , 2012, Annals of Surgical Oncology.

[22]  T. Choueiri,et al.  Sunitinib rechallenge in metastatic renal cell carcinoma patients , 2010, Cancer.

[23]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Weichenthal,et al.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.